

CURRICULUM VITAE FOR ACADEMIC PROMOTION
The Johns Hopkins University School of Medicine

Sandeep Nayak MD

Sept 3, 2025

DEMOGRAPHIC INFORMATION

Current Appointments

University

2022-present Assistant Professor, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

Leadership Positions

2022-present Medical Director, Center for Psychedelic and Consciousness Research, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

Personal Data

Center for Psychedelic and Consciousness Research
CPCR
5510 Nathan Shock Blvd
Baltimore, MD 21224
410-955-0146
smn@jhmi.edu

Education and Training (in chronological order)

Undergraduate

2012 B.A., Religious Studies, Brown University, Providence, RI

Doctoral/graduate

2016 M.D., Warren Alpert School of Medicine, Brown University, Providence, RI

Postdoctoral

2016-2020 Resident, Psychiatry, Johns Hopkins Hospital, Baltimore, MD

2020-2022 Postdoctoral Fellow, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD

Professional Experience

2020-2022 Assistant/Postdoctoral Fellow, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

2022-present Assistant Professor, Center for Psychedelic and Consciousness Research, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

RESEARCH ACTIVITIES

Publications

Original Research [OR]

1. Zaller, N. D., Yokell, M. A., **Nayak, S. M.**, Fu, J. J., Bazazi, A. R., & Rich, J. D. (2012). Syringe acquisition experiences and attitudes among injection drug users undergoing short-term opioid detoxification in Massachusetts and Rhode Island. *Journal of Urban Health*, 89(4), 659–670.

2. Kerr, C. E., Agrawal, U., & **Nayak, S. M.** (2016). The effects of Tai Chi practice on intermuscular beta coherence and the rubber hand illusion. *Frontiers in Human Neuroscience*, 10(37).
3. **Nayak, S. M.**, Huhn, A. S., Bergeria, C. L., Strain, E. C., & Dunn, K. E. (2021). Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder. *Drug and Alcohol Dependence*, 221, 108649.
4. **Nayak, S. M.**, Gukasyan, N., Barrett, F. S., Erowid, E., Erowid, F., & Griffiths, R. R. (2021). Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. *Pharmacopsychiatry*, 54(05), 240-245.
5. Huhn, A. S., Strain, E. C., Jardot, J., Turner, G., Bergeria, C. L., **Nayak, S. M.**, & Dunn, K. E. (2022). Treatment disruption and childcare responsibility as risk factors for drug and alcohol use in persons in treatment for substance use disorders during the COVID-19 crisis. *Journal of Addiction Medicine*, 16(1), e8-e15.
6. Zeifman, R. J., Yu, D., Singhal, N., Wang, G., **Nayak, S. M.**, & Weissman, C. R. (2022). Decreases in suicidality following psychedelic therapy: a meta-analysis of individual patient data across clinical trials. *The Journal of Clinical Psychiatry*, 83(2), 39235.
7. **Nayak, S.M.** & Griffiths R.R. (2022). A single belief-changing psychedelic experience is associated with increased attribution of consciousness to living and non-living entities. *Frontiers in Psychology*, 13.
8. Sweeney, M. M., **Nayak, S.M.**, Hurwitz, E. S., Mitchell, L. N., Swift, T. C., & Griffiths, R. R. (2022). Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. *PloS one*, 17(8), e0271926.
9. **Nayak, S. M.**, Bari, B. A., Yaden, D. B., Spriggs, M. J., Rosas, F. E., Peill, J. M., Giribaldi, B., Erritzoe, D., Nutt, D.J., & Carhart-Harris, R. (2023). A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression. *Psychedelic Medicine*.
10. **Nayak, S. M.**, Singh, M., Yaden, D. B., & Griffiths, R. R. (2023). Belief changes associated with psychedelic use. *Journal of Psychopharmacology*, 37(1), 80-92.
11. Mathai, D.S., **Nayak, S.M.**, Yaden, D.B., & Garcia-Romeu, A. (2023). Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. *Psychopharmacology*.
12. **Nayak, S.M.**, Bradley, M.K., Kleykamp, B.A., Strain, E.C., Dworkin, R.H. & Johnson, M.W. (2023). Control Conditions in Randomized Trials of Psychedelics: An ACITION Systematic Review. *The Journal of Clinical Psychiatry*.
13. Gukasyan, N., Griffiths, R.R., Yaden, D.B., Antoine, D.G., **Nayak, S.M.** (2023). Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. *Journal of Psychopharmacology*.
14. **Nayak, S. M.**, Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., ... & Garcia-Romeu, A. (2023). Naturalistic Psilocybin Use is Associated with Persisting Improvements in Mental Health and Well-being: Results from a Prospective, Longitudinal Survey. *Frontiers in Psychiatry*, 14, 1199642.
15. Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., ... **Nayak, S.M.**, ... & Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. *JAMA*.
16. Davis, A. K., Timmermann, C., Ortiz Bernal, A. M., Lancelotta, R., **Nayak, S. M.**, Sepeda, N. D., Nikolaidis, A., & Griffiths, R. R. (2024). Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences. *Journal of Psychoactive Drugs*
17. Barnett, B. S., Anand, A., Dewey, E. N., Smith, D., **Nayak, S. M.**, Bruckman, D., & Weleff, J. (2024). Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide’s Risk Profile More Favorably? *Psychedelic Medicine*, 0(0), null. <https://doi.org/10.1089/psymed.2023.0027>
18. Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., **Nayak, S.M.**, Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. *PLOS ONE*, 19(3), e0300501. <https://doi.org/10.1371/journal.pone.0300501>
19. Hinkle, J. T., Graziosi, M., **Nayak, S. M.**, & Yaden, D. B. (2024). Adverse events in studies of classic psychedelics: A systematic review and meta-analysis. *JAMA psychiatry*.

20. Wang, E., Mathai, D. S., Gukasyan, N., **Nayak, S.**, & Garcia-Romeu, A. (2024). Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. *Scientific Reports*, 14(1), 1–13.
21. Jones, G., Lowe, M. X., **Nayak, S.**, Sepeda, N., Kettner, H., Carhart-Harris, R., ... & Garcia-Romeu, A. (2025). Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. participants of Color: A longitudinal online survey study. *Journal of Affective Disorders*.
22. **Nayak, S. M.**, White, S. H., Hilbert, S. N., Lowe, M. X., Jackson, H., Griffiths, R. R., ... & Yaden, D. B. (2025). Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study. *Journal of Psychoactive Drugs*, 1-10.
23. Singleton, S. P., Sevchik, B. L., Vandekar, S. N., Strain, E. C., **Nayak, S. M.**, Dworkin, R. H., ... & Satterthwaite, T. D. (2025). An initiative for living evidence synthesis in clinical psychedelic research. *Nature Mental Health*, 3(1), 3-5.
24. Yaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., ... **S. M. Nayak**, ... & Yaden, M. E. (2025). A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. *Psychedelic Medicine*, 3(1), 1-18.
25. Mathai, D. S., Roberts, D. E., **Nayak, S. M.**, Sepeda, N. D., Lehrner, A., Johnson, M. W., Lowe, M. X., Jackson, H., & Garcia-Romeu, A. (2025). Shame, guilt, and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use. *Journal of Psychoactive Drugs*.
<https://doi.org/10.1080/02791072.2025.2461997>
26. Richard, J., Scott, J., **Nayak, S. M.**, Sepeda, N. D., Lowe, M. X., Jackson, H., & Garcia-Romeu, A. (2025). Patterns of internalizing problems, substance use and cognitive flexibility before and after naturalistic psilocybin use: A repeated measures latent profile analysis. *International Journal of Mental Health and Addiction*. <https://doi.org/10.1007/s11469-025-01489-z>
27. Richard, J., **Nayak, S. M.**, Sepeda, N., & Garcia-Romeu, A. (2025). Latent class analysis of changes in substance use and depressive symptoms following naturalistic psilocybin use: Results from a prospective longitudinal survey. *Drug and Alcohol Dependence*, 267, 112184.
<https://doi.org/10.1016/j.drugalcdep.2025.112184>
28. Bender, D. A., **Nayak, S. M.**, Siegel, J. S., Hellerstein, D. J., Ercal, B. C., & Lenze, E. J. (2025). Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners. *The Journal of clinical psychiatry*, 86(1), 24m15521.
29. Bender, D. A., **Nayak, S. M.**, Siegel, J. S., Hellerstein, D. J., Ercal, B. C., & Lenze, E. J. (2025). The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings. *American Journal of Psychotherapy*, appi-psychotherapy.
30. Goldy, S. P., Du, B. A., Rohde, J. S., **Nayak, S. M.**, Strickland, J. C., Ehrenkranz, R., ... & Yaden, D. B. (2025). Psychedelic risks and benefits: A cross-sectional survey study. *Journal of Psychopharmacology*, 02698811241292951.

Review Articles [RA]

1. **Nayak, S. M.**, & Johnson, M. W. (2021). Psychedelics and psychotherapy. *Pharmacopsychiatry*, 54(4), 167–175.
2. Yaden, D. B., Johnson, M. W., Griffiths, R. R., Doss, M., Garcia-Romeu, A., **Nayak, S. M.**, Gukasyan, N., Mathur, B. N., & Barrett, F. S. (2021). Psychedelics and consciousness: distinctions, demarcations, and opportunities. *International Journal of Neuropsychopharmacology*.
3. Yaden, D. B., **Nayak, S. M.**, Gukasyan, N., Anderson, B. T., & Griffiths, R. R. (2021). The potential of psychedelics for end of life and palliative care.
4. Gukasyan, N., & **Nayak, S. M.** (2022). Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. *Transcultural Psychiatry*, 59(5), 652-664.
5. Graziosi, M., Singh, M., **Nayak, S.M.**, Yaden, D.B. (2023). Acute Subjective Effects of Psychedelics within and Beyond WEIRD Contexts, *Journal of Psychoactive Drugs*, DOI: 10.1080/02791072.2023.2255274
6. Yaden, D. B., Berghella, ... **Nayak, S.M.**, ... & Garcia-Romeu, A. (2023). IUPHAR-review: The Integration of Classic Psychedelics into Current Substance Use Disorder Treatment Models. *Pharmacological Research*,

106998.

7. Dworkin, H.R., McDermott, M.P., **Nayak, S.M.**, Strain, E.C. (2023). Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts? *Clinical Pharmacology & Therapeutics*.
8. Meling, D., Ehrenkranz, R., **Nayak, S. M.**, Aicher, H. D., Funk, X., van Elk, M., Graziosi, M., Bauer, P. R., Scheidegger, M., & Yaden, D. B. (2024). Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression. *Psychoactives*, 3(2), Article 2. <https://doi.org/10.3390/psychoactives3020014>
9. Jacobs, E., Earp, B. D., Appelbaum, P. S., Bruce, L., Cassidy, K., Celidwen, Y., ... **Nayak, S.M.**, ... Yaden, D. B. (2024). The Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group Consensus Statement. *The American Journal of Bioethics*, 1–7. <https://doi.org/10.1080/15265161.2024.2342764>
10. O'Donnell, K.C., Anderson, B.T., Barrett, ... **Nayak, S.M.**, ... & Gukasyan, N. (2024). Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy. *American Journal of Psychiatry*, 181(1), 74–75.
11. Ehrenkranz, R., Agrawal, M., **Nayak, S. M.**, & Yaden, D. B. (2024). Adverse Events Should Not Be Surprising in Psychedelic Research. *Psychedelic Medicine*.
12. Barnett, B. S., Vest, M. F., Delatte, M. S., King IV, F., Mauney, E. E., Coulson, A. J., **Nayak, S.M.**, ... & Murnane, K. S. (2024). Practical considerations in the establishment of psychedelic research programs. *Psychopharmacology*, 1-17.
13. **Nayak, S. M.**, & Zahid, Z. (2025). Out of control: Blinding, dose response, and psychosocial controls in psychedelic trials. *Journal of Psychopharmacology*, 0(0). <https://doi.org/10.1177/02698811251368367>

Case Reports [CR] None

Book Chapters [BC]

1. **Nayak, S.M.**, Brigham, J., Gerstenblith, T.A., & Prince, E. (2022). Psychopharmacology in the Critical Care Setting. In K. J. Stucky, P. & J. E. Jutte (Eds.), *Critical Care Psychology and Rehabilitation*. (pp. 235–250). Oxford University Press.
2. **Nayak, S.M.** & Johnson, M.W., (2023). Hallucinogen and MDMA-Related Disorders. In Tasman, A., Riba, M., Schulze, T., Ng, C., Alfonso, C., Lecic-Tosevski, D., Kanba, S., Alarcón, R. & Ndeti, D (Eds.), *Tasman's Psychiatry* (5th ed.). Springer.
3. Yaden, D.B., **Nayak, S.M.**, Griffiths, R.R. (2024). Belief change and agnostic frames in psychedelic research and clinical contexts. In Letheby, C., Gerrans, P ((Eds.), *Philosophical Perspectives on Psychedelic Psychiatry, International Perspectives in Philosophy and Psychiatry* (online ed.). Oxford Academic.

Editorials [ED]

1. Yaden, D. B., Gukasyan, N., **Nayak, S.M.** (2023). Psilocybin in Bipolar II Study Provides Preliminary Data on Safety. *JAMA Psychiatry*. doi:10.1001/jamapsychiatry.2023.4680
2. Dworkin, H.R., McDermott, M.P., **Nayak, S.M.**, Strain, E.C. (2023). Reply to “Capturing synergy holistically in psychedelic clinical trials” *Clinical Pharmacology & Therapeutics*.

FUNDING

EXTRAMURAL Funding

Research Extramural Funding

Current

2024-2027 Gracias Family Foundation
Gift to support a psilocybin + MDMA study in a PTSD sample.
\$1,900,000
Role: Co-PI

2024-

Fifth Generation Funds for PTSD
Gift to support PTSD studies with psychedelics

\$1,500,000

Role: PI

Pending: none

Previous: none

CLINICAL ACTIVITIES

Certification

Medical, other state/government licensure (date, identification #)

2019 - present Maryland #D88663

Boards, other specialty certification (date, identification #)

2020 American Board of Psychiatry and Neurology; Psychiatry #77811

Clinical (Service) Responsibilities

2020 - present Addiction Treatment Services, psychiatric outpatient clinic, 1 day / week

2022 - present Inpatient attending, Bayview Medical Center, 1 month / year

EDUCATIONAL ACTIVITIES

Teaching

Classroom instruction

2018 – 2020 Brain, Mind, Behavior course, lecturer and course developer for 1st year medical students, Johns Hopkins University School of Medicine, Baltimore, MD

CME instruction

Nov 2020 Introduction to Psychedelic Therapy for Addiction Medicine, Panelist, Horizons, New York, NY

Jun 2022 An Overview of Psilocybin-Assisted Therapy for Psychiatric Conditions. Presentation. Psychedelics in Psychiatry, Idaho Psychiatric Association 2022 Annual CME conference. Boise, Idaho.

Jun 2022 Panel discussion – Psychedelics in Psychiatry, Idaho Psychiatric Association 2022 Annual CME conference. Boise, Idaho.

March 2023 Psychedelic-Assisted Psychotherapy: an overview of empirical utility, rationale, and future clinical considerations. The Ross Center. New York.

March 2023 Psychedelic-Assisted Psychotherapy: an overview of empirical utility, rationale, and future clinical considerations. Pennsylvania Psychiatric Society - Colloquium of Scholars. Philadelphia.

April 2023 Psychedelic-Assisted Psychotherapy: an overview of empirical utility, rationale, and future clinical considerations. Bermuda Hospitals Board - CME Series. Bermuda.

May 2023 Psilocybin-assisted psychotherapy: empirical uses and psychological mechanisms. Tumulty Topics regional CME course. Baltimore.

Mentoring

Research Program Coordinators

Postdoctoral Research Fellow Advisees

Medical Student Advisees

Faculty Advisees

2023- Brandon Weiss, PhD, Johns Hopkins University School of Medicine.
One study funded by philanthropic gift. One manuscript published. One study in progress.

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES none ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

As Medical Director of the Center for Psychedelic and Consciousness Research, I oversee clinical research investigating the therapeutic potential of psychedelics for mental health and neurological disorders. I provide medical oversight for all study protocols, ensure participant safety, and collaborate with an interdisciplinary team of researchers, psychiatrists, nurses, and study staff. I am responsible for the medical aspects of all psychedelic research studies at the CPR.

Editorial Activities

Journal Reviewer

ACS Pharmacology & Translational Science, Addiction Science and Clinical Practice, American Journal of Psychotherapy, Frontiers in Psychiatry, Harvard Review of Psychiatry, Journal of Psychedelic Studies, Journal of Psychoactive Drugs Psychopharmacology, Drug and Alcohol Dependence, Psychological Medicine, Journal of Addiction Medicine, Psychedelic Medicine, Lancet Psychiatry, International Review of Psychiatry

Other peer review activities

2019-2020 Content Editor, Johns Hopkins Psychiatry Guide

Advisory Committees, Review Groups/Study Sections none

Professional Societies American Psychiatric Association

Conference Organizer, Session Chair none

Consultantships none

RECOGNITION

Awards, Honors

2018 BPRU Travel Award to College on Problems of Drug Dependence

Invited Talks, Panels

Invited Talks

JHMI/Regional

Nov 2023 Psilocybin for substance use disorders: overview of current research and future directions.
Psychiatry Grand Rounds. Johns Hopkins Hospital. Baltimore.

National

Oct 2021 Belief Changes Following a Single Psychedelic Experience. Translational Psychedelic Research

(TrPR) Program, University of California San Francisco

Dec 2021	What can psychiatry learn from psychedelics? Panel discussion. Horizons 2021 Conference. New York.
Oct 2022	An overview of psychedelic assisted psychotherapy. Massachusetts General Hospital PGY-2 psychiatry residency didactic, Massachusetts General Hospital, Boston.
Oct 2022	What Have Human Neuroimaging and Animal Models Taught Us About Therapeutic Mechanisms of Psychedelics? Keynote speaker. The Neuroscience of Using Hallucinogens in Treating Depression and PTSD Conference. Montclair State University, NJ.
Oct 2022	Emerging indications for psychedelic therapies. Horizons 2022 Conference. New York.
Oct 2022	Psychedelic professions and professionals. Panel discussion. Horizons 2022 Conference. New York.
Nov 2022	Psychedelic assisted psychotherapy for depression. Massachusetts General Hospital Annual Conference on Psychedelics and Psychedelic Medicine. Boston.
May 2023	Classic psychedelics and drug interactions. Psychedelic Therapeutics and Drug Development Conference. San Francisco
May 2023	Blinding, control conditions, and causal inference in psychedelic trials. Stanford Psychedelic Science Group. Palo Alto.
May 2023	Cultural Psychiatry and Psychedelics. APA Annual meeting. San Francisco.
May 2023	Ethics in psychedelics: Equity, access, consent, clinical boundaries, and characterizing the acute subjective effects. APA Annual meeting. San Francisco.
Jul 2023	Naturalistic Psilocybin Use is Associated with Persisting Improvements in Mental Health and Well-being in a Large Prospective Sample. Psychedelic Science 2023. Denver.
Jan 2024	Psychedelic-Assisted Psychotherapy: an overview of empirical utility, rationale, and future clinical considerations. Psychiatry Grand Rounds. University of South Carolina. Greenville.
Feb 2024	Psychedelic-Assisted Psychotherapy: an overview of empirical utility, rationale, and future clinical considerations. West Hudson Psychiatric Society.
April 2024	Bipartisan Mental Health and Substance Use Task Force Roundtable. Washington DC.
May 2024	Survey of leading psychedelic-assisted therapy trials. Horizons Annual Meeting 2024. New York.
Jun 2024	Introduction to Psychedelics for the Treatment of Substance Use Disorder. National Council for Mental Wellbeing. Washington DC.
Aug 2024	Control Conditions in Psychedelic Trials. Hopkins-Oxford Psychedelic Ethics Conference. Washington DC.
Nov 2024	Use & Misuse of Plant-Based Drugs Panel. Symposium on Substance Use Research. Virtual. University of Nebraska Lincoln.
Jun 2025	Introduction to Psychedelic Therapy for the Treatment of Addiction. Psychedelic Science Conference 2025. Denver

International

Sep 2021	How useful is integration therapy? Panel discussion. INSIGHT 2021 Conference. Berlin.
Feb 2022	Blinding, control conditions, and causal inference in psychedelic trials. Neurobiology Research Unit, Copenhagen University Hospital.
Apr 2022	La toxicidad, potencial de abuso y daños a la salud pública del uso de la psilocibina. Psilocibina, Innovación para la Salud Mental, Senate of the Republic of Mexico, Mexico city.
Jan 2023	Belief changes associated with psychedelic use. Catalan Society of Psychiatry and Mental Health. Barcelona.
May 2023	Uso de Psilocibina y otros psicodélicos. Posibles indicaciones en condiciones psiquiátricas. Fundación Santa Fe Hospital. Bogotá.
May 2023	Posibles beneficios de los psicodélicos en cuidados paliativos. Fundación Santa Fe Hospital. Bogotá.
May 2023	MDMA y evidencia en el trastorno de estrés postraumático. Fundación Santa Fe Hospital. Bogotá.

Aug 2023	The unique nature of psychedelic therapy: methodological challenges. European Behavioral Pharmacology Society Biennial Meeting. Mannheim, Germany.
Aug 2023	Ethics of antidepressants in psychedelic clinical trials. Oxford Psychedelic Ethics Workshop. Oxford.
Sept 2023	Psychedelics and Spirituality panel. Insight 2023 conference. Berlin.
Sept 2023	The Varieties of Indigenous Practices - Diversity of Psychedelic Use. Insight 2023 conference. Berlin.
Oct 2023	Is Psychedelic Therapy Just Psychotherapy? Finnish Association for Psychedelic Research. Helsinki.
Oct 2023	Terapia psicodélica: métodos, neurociencia e interacciones farmacológicas. Universidad de los Andes. Bogotá.
Sept 2024	Gaps in Psychedelic Medicine. Mystic Summit. Necker Island, British Virgin Islands.
Sept 2024	Is psychotherapy required in psychedelic therapy? European College of Neuropsychopharmacology Annual Meeting 2024. Milan.
Sept 2025	Practical strategies for representative recruitment in psychedelic trials. Hopkins Oxford Psychedelic Ethics Annual Meeting. 2025. Oxford.

Conference and Workshop Presentations

Includes only those talks or posters presented by S. Nayak; excludes invited talks

Sep 2021	Belief Changes Following a Single Psychedelic Experience. Presentation. INSIGHT 2021 Conference. Berlin.
Sep 2021	Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures. Poster. INSIGHT 2021 Conference. Berlin.
Dec 2021	Psilocybin-Assisted Therapy for Tobacco Smoking Cessation. Presentation. Horizons 2021 Conference. New York.
Feb 2024	Classic psychedelics and drug interactions. International Society for Research on Psychedelics Conference 2024. New Orleans.
May 2024	History of Psychedelics in Psychiatry and Introduction to Psychedelic-Assisted Therapy. APA Annual Meeting 2024. New York.
May 2024	Pharmacology: Classic psychedelics and MDMA. APA Annual Meeting 2024. New York.

OTHER PROFESSIONAL ACCOMPLISHMENTS none